International Journal of Cancer Management

Published by: Kowsar

Effect of Hypofractionation on Prostate Cancer Radiotherapy

Abolfazl Arabpour 1 and Daryoush Shahbazi-Gahrouei 2 , *
Authors Information
1 Nuclear and Radiological/Biomedical Engineering Department, University of Florida, Gainesville, FL 32611, USA
2 Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Article information
  • International Journal of Cancer Management: October 2017, 10 (10); e12204
  • Published Online: October 28, 2017
  • Article Type: Review Article
  • Received: May 30, 2017
  • Revised: July 22, 2017
  • Accepted: October 22, 2017
  • DOI: 10.5812/ijcm.12204

To Cite: Arabpour A, Shahbazi-Gahrouei D. Effect of Hypofractionation on Prostate Cancer Radiotherapy, Int J Cancer Manag. 2017 ; 10(10):e12204. doi: 10.5812/ijcm.12204.

Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Coutard H. Roentgen therapy of epitheliomas of the tonsillar region, hypopharynx and larynx from 1920 to 1926. Am J Roentgenol. 1932;28:313-31.
  • 2. Weissberg JB, Prosnitz LR. Treatment of early breast cancer with primary radiation therapy: rationale, results, and techniques. Bull N Y Acad Med. 1982;58(2):203-13. [PubMed: 6956406].
  • 3. Shahbazi Gahrouei D. Radiobiological modeling in radiation oncology. J Radiobiol. 2014;1(1):17-8. doi: 10.15171/jrb.2014.05.
  • 4. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005;44(3):265-76. doi: 10.1080/02841860410002824. [PubMed: 16076699].
  • 5. Shahbazi-Gahrouei D, Abdolahi M, Zarkesh-Esfahani SH, Laurent S, Sermeus C, Gruettner C. Functionalized magnetic nanoparticles for the detection and quantitative analysis of cell surface antigen. Biomed Res Int. 2013;2013:349408. doi: 10.1155/2013/349408. [PubMed: 23484112].
  • 6. Shahbazi Gahrouei D, Gookizadeh A, Abdollahi M. Comparison of conventional radiotherapy techniques with different energies in treating prostate cancer, employing a designed pelvis phantom. J Med Sci. 2008;8(4):429-32. doi: 10.3923/jms.2008.429.432.
  • 7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107. [PubMed: 21296855].
  • 8. Shahbazi-Gahrouei D, Saeb M, Monadi S, Jabbari I. Clinical Implications of TiGRT Algorithm for External Audit in Radiation Oncology. Adv Biomed Res. 2017;6:117. doi: 10.4103/abr.abr_268_16. [PubMed: 28989910].
  • 9. Karbalaee M, Shahbazi-Gahrouei D, Tavakoli MB. An Approach in Radiation Therapy Treatment Planning: A Fast, GPU-Based Monte Carlo Method. J Med Signals Sens. 2017;7(2):108-13. [PubMed: 28553584].
  • 10. Rezaee V, Shahbazi Gahrouei D, Monadi S, Saeb M. Evaluation of error doses of treatment planning software using solid anthropomorphic phantom. J Isfahan Med Sch. 2016;34(393):908-13.
  • 11. Abdolahi M, Shahbazi-Gahrouei D, Laurent S, Sermeus C, Firozian F, Allen BJ, et al. Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb-conjugated SPIONs for specific detection of prostate cancer. Contrast Media Mol Imaging. 2013;8(2):175-84. doi: 10.1002/cmmi.1514. [PubMed: 23281290].
  • 12. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262. [PubMed: 25651787].
  • 13. Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin Oncol (R Coll Radiol). 1991;3(3):127-32. [PubMed: 2069876].
  • 14. Livsey JE, Cowan RA, Wylie JP, Swindell R, Read G, Khoo VS, et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys. 2003;57(5):1254-9. [PubMed: 14630259].
  • 15. Miles EF, Lee WR. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol. 2008;18(1):41-7. doi: 10.1016/j.semradonc.2007.09.006. [PubMed: 18082587].
  • 16. Hoffmann AL, Nahum AE. Fractionation in normal tissues: the (alpha/beta)eff concept can account for dose heterogeneity and volume effects. Phys Med Biol. 2013;58(19):6897-914. doi: 10.1088/0031-9155/58/19/6897. [PubMed: 24029492].
  • 17. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62(740):679-94. doi: 10.1259/0007-1285-62-740-679. [PubMed: 2670032].
  • 18. Chapman JD. Single hit mechanism of tumour cell killing by radiation. Int J Radiat Biol. 2003;79(2):71-81. [PubMed: 12569011].
  • 19. Nahum AE. The radiobiology of hypofractionation. Clin Oncol (R Coll Radiol). 2015;27(5):260-9. doi: 10.1016/j.clon.2015.02.001. [PubMed: 25797579].
  • 20. Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2003;57(2):391-401. [PubMed: 12957250].
  • 21. Carlone M, Wilkins D, Raaphorst P. The modified linear-quadratic model of Guerrero and Li can be derived from a mechanistic basis and exhibits linear-quadratic-linear behaviour. Phys Med Biol. 2005;50(10):9-13. doi: 10.1088/0031-9155/50/10/B01. [PubMed: 15876677].
  • 22. Wang JZ, Huang Z, Lo SS, Yuh WT, Mayr NA. A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy. Sci Transl Med. 2010;2(39):39-48. doi: 10.1126/scitranslmed.3000864. [PubMed: 20610850].
  • 23. Sheu T, Molkentine J, Transtrum MK, Buchholz TA, Withers HR, Thames HD, et al. Use of the LQ model with large fraction sizes results in underestimation of isoeffect doses. Radiother Oncol. 2013;109(1):21-5. doi: 10.1016/j.radonc.2013.08.027. [PubMed: 24060173].
  • 24. Mehta N, King CR, Agazaryan N, Steinberg M, Hua A, Lee P. Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent dose and local control. Pract Radiat Oncol. 2012;2(4):288-95. doi: 10.1016/j.prro.2011.10.004. [PubMed: 24674167].
  • 25. Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?. Int J Radiat Oncol Biol Phys. 2014;88(2):254-62. doi: 10.1016/j.ijrobp.2013.07.022. [PubMed: 24411596].
  • 26. Baker C, Carver A, Nahum A. PO 0910, Local control prediction for NSCLC using a common LQbased TCP model for both SABR and 3D CRT fractionation. Radiother Oncol. 2015;115:471. doi: 10.1016/s0167-8140(15)40902-8.
  • 27. Song CW, Cho LC, Yuan J, Dusenbery KE, Griffin RJ, Levitt SH. Radiobiology of stereotactic body radiation therapy/stereotactic radiosurgery and the linear-quadratic model. Int J Radiat Oncol Biol Phys. 2013;87(1):18-9. doi: 10.1016/j.ijrobp.2013.03.013. [PubMed: 23608235].
  • 28. Withers HR, Thames HD, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol. 1983;1(2):187-91. [PubMed: 6680223].
  • 29. Fenwick JD, Lawrence GP, Malik Z, Nahum AE, Mayles WP. Early mucosal reactions during and after head-and-neck radiotherapy: dependence of treatment tolerance on radiation dose and schedule duration. Int J Radiat Oncol Biol Phys. 2008;71(2):625-34. doi: 10.1016/j.ijrobp.2008.02.008. [PubMed: 18474317].
  • 30. Strigari L, Pedicini P, D'Andrea M, Pinnaro P, Marucci L, Giordano C, et al. A new model for predicting acute mucosal toxicity in head-and-neck cancer patients undergoing radiotherapy with altered schedules. Int J Radiat Oncol Biol Phys. 2012;83(5):697-702. doi: 10.1016/j.ijrobp.2012.02.004. [PubMed: 22578541].
  • 31. Mayles P, Nahum A, Rosenwald J. Handbook of radiotherapy physics, theory and practice. Florida, United States: CRC Press; 2007.
  • 32. Mavroidis P, Ferreira BC, Papanikotaou N, Svensson R, Kappas C, Lind BK, et al. Assessing the difference between planned and delivered intensity-modulated radiotherapy dose distributions based on radiobiological measures. Clin Oncol (R Coll Radiol). 2006;18(7):529-38. [PubMed: 16969983].
  • 33. Brenner DJ. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys. 2004;60(4):1013-5. doi: 10.1016/j.ijrobp.2004.04.014. [PubMed: 15519768].
  • 34. Kallman P, Agren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol. 1992;62(2):249-62. [PubMed: 1355519].
  • 35. Liao Y, Joiner M, Huang Y, Burmeister J. Hypofractionation: what does it mean for prostate cancer treatment?. Int J Radiat Oncol Biol Phys. 2010;76(1):260-8. doi: 10.1016/j.ijrobp.2009.06.043. [PubMed: 19879698].
  • 36. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol). 2007;19(5):289-301. doi: 10.1016/j.clon.2007.02.007. [PubMed: 17517328].
  • 37. Woynarowska BA, Roberts K, Woynarowski JM, MacDonald JR, Herman TS. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells. Radiat Res. 2000;154(4):429-38. [PubMed: 11023607].
  • 38. Bromfield GP, Meng A, Warde P, Bristow RG. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis. 2003;6(1):73-85. doi: 10.1038/sj.pcan.4500628. [PubMed: 12664070].
  • 39. Leith JT, Quaranto L, Padfield G, Michelson S, Hercbergs A. Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: x-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo. Int J Radiat Oncol Biol Phys. 1993;25(2):283-7. [PubMed: 8420876].
  • 40. Algan O, Stobbe CC, Helt AM, Hanks GE, Chapman JD. Radiation inactivation of human prostate cancer cells: the role of apoptosis. Radiat Res. 1996;146(3):267-75. [PubMed: 8752304].
  • 41. Yarnold J, Bentzen SM, Coles C, Haviland J. Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. Int J Radiat Oncol Biol Phys. 2011;79(1):1-9. doi: 10.1016/j.ijrobp.2010.08.035. [PubMed: 20950960].
  • 42. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82(1):17-24. doi: 10.1016/j.ijrobp.2010.10.075. [PubMed: 21324610].
  • 43. Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, et al. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol. 2005;75(1):74-82. doi: 10.1016/j.radonc.2004.12.019. [PubMed: 15878104].
  • 44. Fowler JF, Tome WA, Fenwick JD, Mehta MP. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys. 2004;60(4):1241-56. doi: 10.1016/j.ijrobp.2004.07.691. [PubMed: 15519797].
  • 45. Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol). 2008;20(10):729-37. doi: 10.1016/j.clon.2008.08.006. [PubMed: 18838256].
  • 46. Hoskin PJ, Dearnaley DP. Hypofractionation in clinical trials for prostate cancer. Clin Oncol. 2007;19(5):287-8. doi: 10.1016/j.clon.2007.03.007.
  • 47. Khoo VS, Dearnaley DP. Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer--the CHHiP trial. Clin Oncol (R Coll Radiol). 2008;20(1):12-4. doi: 10.1016/j.clon.2007.10.008. [PubMed: 18036791].
  • 48. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50(4):1021-31. [PubMed: 11429230].
  • 49. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52(1):6-13. [PubMed: 11777617].
  • 50. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: what is it, really?. Radiother Oncol. 2005;76(1):1-3. doi: 10.1016/j.radonc.2005.06.009. [PubMed: 15990189].
  • 51. Williams SG, Taylor JM, Liu N, Tra Y, Duchesne GM, Kestin LL, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68(1):24-33. doi: 10.1016/j.ijrobp.2006.12.036. [PubMed: 17448868].
  • 52. Hoskin PJ. Hypofractionation in prostate cancer, How far can we go?. Clin Oncol. 2008;20(10):727-8. doi: 10.1016/j.clon.2008.09.002.
  • 53. Chin YS, Bullard J, Bryant L, Bownes P, Ostler P, Hoskin PJ. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol). 2006;18(6):474-9. [PubMed: 16909971].
  • 54. Ritter MA, Forman JD, Kupelian PA, Petereit DG, Lawton C, Walker W, et al. A phase I, II trial of dose per fraction escalation for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;69(3):174. doi: 10.1016/j.ijrobp.2007.07.315.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments